Clinical Trial Update: Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating AZLI, an inhaled antibiotic, in adults with Non-Cystic Fibrosis bronchiectasis has completed. The study's results, focusing on safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• AZLI (Aztreonam for inhalation)

Snippet

Sponsor: Gilead Sciences | Conditions: Bronchiectasis | Phase 3 | Status: COMPLETED | Results posted: 2014-04-16